Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable - S&P Global Ratings’ Credit Research

Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable

Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable - S&P Global Ratings’ Credit Research
Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable
Published Feb 13, 2018
5 pages (2171 words) — Published Feb 13, 2018
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

On Feb. 2, 2018, STADA Arzneimittel AG's shareholders approved the public takeover of STADA by Nidda Healthcare Holding GmbH. We view positively the Nidda group's size, diversification, and track record of generating cash flow. We are assigning our 'B+' long-term issuer credit rating to Nidda BondCo GmbH (Nidda), the parent of Nidda Healthcare. The stable outlook reflects our view that Nidda will remain resilient and continue to display solid operating performance and generate sufficient earnings to support its expansion. PARIS (S&P Global Ratings) Feb. 13, 2018--S&P Global Ratings today assigned its 'B+' long-term issuer credit rating to Nidda BondCo GmbH (Nidda), the parent of the group's holding company, Nidda Healthcare Holding AG (Nidda Healthcare). The outlook is stable. At the

  
Brief Excerpt:

...+ On Feb. 2, 2018, STADA Arzneimittel AG's shareholders approved the public takeover of STADA by Nidda Healthcare Holding GmbH. + We view positively the Nidda group's size, diversification, and track record of generating cash flow. + We are assigning our 'B+' long-term issuer credit rating to Nidda BondCo GmbH (Nidda), the parent of Nidda Healthcare. + The stable outlook reflects our view that Nidda will remain resilient and continue to display solid operating performance and generate sufficient earnings to support its expansion. PARIS (S&P Global Ratings) Feb. 13, 2018--S&P Global Ratings today assigned its 'B+' long-term issuer credit rating to Nidda BondCo GmbH (Nidda), the parent of the group's holding company, Nidda Healthcare Holding AG (Nidda Healthcare). The outlook is stable. At the same time, we assigned our 'B+' long-term issue rating to the group's senior secured debt, including a 1.7 billion term loan B, 735 million senior secured notes, and a 400 million revolving credit facility...

  
Report Type:

Ratings Action

Ticker
1509417D@GR
Issuer
Nidda BondCo GmbH
Sector
Global Issuers
Country
Germany
Region
Europe, Middle East, Africa
Format:
PDF Adobe Acrobat
Buy Now

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable" Feb 13, 2018. Alacra Store. May 15, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Germany-Based-Generic-Pharma-Co-Nidda-BondCo-GmbH-Assigned-B-Rating-Outlook-Stable-1993325>
  
APA:
S&P Global Ratings’ Credit Research. (). Germany-Based Generic Pharma Co. Nidda BondCo GmbH Assigned 'B+' Rating; Outlook Stable Feb 13, 2018. New York, NY: Alacra Store. Retrieved May 15, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Germany-Based-Generic-Pharma-Co-Nidda-BondCo-GmbH-Assigned-B-Rating-Outlook-Stable-1993325>
  
US$ 150.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.